IP Library Granted Patent US 9,060,998
Granted Patent B2
US 9,060,998 · App. 13/888,949 · Granted Jun 23, 2015

Use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin

Inventor: Eggert Stockfleth (Albersdorf, DE)
Assignee: Medigene AG
A61K31/353A61K31/7048A61K36/82
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,060,998
App. No.
13/888,949
Granted
Jun 23, 2015
Kind
B2
Abstract

The present invention refers to a method for treating cancerous or precancerous lesions of the skin by administering a pharmaceutically effective amount of a polyphenol to a patient as well as to the production of a medicament thereto.

Claims (15)

1. A method for treating a lesion of the skin of a patient, wherein said lesion is Bowen's disease or verucca senilis, said method comprising topically administering to the skin lesion a pharmaceutically effective amount of a polyphenol composition comprising (i) a mixture of polyphenols and (ii) a carrier, wherein the composition comprises from about 5% (w/w) to about 20% (w/w) of the mixture of polyphenols, wherein the mixture of polyphenols contains epicatechol, epicatechol gallate, epigallocatechol, epigallocatechol gallate, and gallocatechol gallate.

2. The method according to claim 1 , wherein the patient is a human.

3. The method according to claim 1 , wherein the polyphenol is isolated from tea or a tea extract.

4. The method according to claim 3 , wherein the tea is a green tea.

5. The method according to claim 3 , wherein the tea extract is a green tea extract.

6. The method according to claim 1 , wherein the mixture of polyphenols contains (−)-epicatechol, (−)-epicatechol gallate, (−)-epigallocatechol, (−)-epigallocatechol gallate, and (−)-gallocatechol gallate.

7. The method according to claim 1 , wherein the mixture of polyphenols contains about 2-20% (w/w) epicatechol, about 2-20% (w/w) epicatechol gallate, about 1-25% (w/w) epigallocatechol, about 40-75% (w/w) epigallocatechol gallate, and about 0.5-20% (w/w) gallocatechol gallate.

8. The method according to claim 7 , wherein the mixture of polyphenols contains about 10.8% (w/w) of (−)-epicatechol, about 6.5% (w/w) of (−)-epicatechol gallate, about 9.2% (w/w) of (−)-epigallocatechol, about 54.8% (w/w) of (−)-epigallocatechol gallate, and about 4.0% (w/w) of (−)-gallocatechol gallate.

9. The method according to claim 1 , wherein the mixture of polyphenols is combined with an additive.

10. The method according to claim 9 , wherein the additive is selected from the group consisting of petroleum jelly, wax, oleyl alcohol, propylene glycol monostearate, propylene glycol monopalmitostearate, and isopropyl myristate.

11. The method according to claim 1 , wherein the polyphenol composition contained in a carrier is selected from the group consisting of an emulsion, a gel, a cream, and an ointment.

12. The method according to claim 1 , wherein the method for treating said lesions is combined with a different anticancer treatment.

13. The method according to claim 12 , wherein the different anticancer treatment is selected from the group consisting of surgery, electrodessication, curettage, excision, Mohs micrographic surgery, radiation, proton therapy, chemotherapy, photodynamic therapy, cryosurgery, laser, immunotherapy, vaccine therapy, and biologic therapy.

14. The method according to claim 1 , wherein the composition comprises about 15% (w/w) mixture of polyphenols.

15. A method for treating a lesion of the skin in a patient, wherein said skin lesion is Bowen's disease or verucca senilis, said method comprising topically administering a pharmaceutically effective amount of a polyphenol composition comprising (i) a mixture of polyphenols and (ii) a carrier, wherein the composition comprises about 15% (w/w) mixture of polyphenols, wherein the mixture of polyphenols contains about 10.8% (w/w) of (−)-epicatechol, about 6.5% (w/w) of (−)-epicatechol gallate, about 9.2% (w/w) of (−)-epigallocatechol, about 54.8% (w/w) of (−)-epigallocatechol gallate, and about 4.0% (w/w) of (−)-gallocatechol gallate.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2018
From: MEDIGENE AG
To: FOUGERA PHARMACEUTICALS INC
Reel/Frame 044603/0099 →
CHANGE OF NAME Recorded Mar 4, 2014
From: MEDIGENE AG
To: MEDIGENE AG
Reel/Frame 032480/0101 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2014
From: STOCKFLETH, EGGERT
To: MEDIGENE AG
Reel/Frame 032135/0526 →
Continuity (4)
Continuation 13051593 · Mar 18, 2011
Continuation 10574422
Provisional Application 60510101 · Oct 9, 2003
Related Publication 20130245113A1 · Sep 19, 2013